top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hFXII mice
Strain Name
C57BL/6N-F12tm1(F12)Bcgen/Bcgen
Common Name  B-hFXII mice
Background C57BL/6N Catalog number  112750
Aliases            HAE3, HAEX, HAF
NCBI Gene ID
2161
Description

FXII is a protease that is primarily produced in the liver and circulates as a single-chain zymogen in plasma, playing an important role in the intrinsic pathway of blood coagulation and hemostasis. Upon contact with negatively charged surfaces, FXII converts into its double-stranded active form, FXIIa. The absence of FXII in humans and mice does not affect normal hemostasis ability, and the lack of FXII can inhibit thrombus formation, making it an important target in thrombosis treatment.
Application: This product is used for pharmacodynamics and safety evaluation of cardiovascular diseases such as thrombosis.


Mechanism of action


from clipboard


Plasmatic coagulation cascade:

Coagulation is triggered by either extrinsic or intrinsic pathways, leading to the generation of thrombin. The extrinsic pathway is initiated during the formation of the TF-FVIIa complex, which activates FX to FXa via FIXa. The intrinsic pathway is initiated by the activation of Factor XII (FXII) mediated by negatively charged surfaces and promotes the generation of thrombin through consecutive activations of FXI, FIX, FX and prothrombin.


Targeting strategy


Gene targeting strategy for B-hFXII mice. 
The exons 1~14 of mouse FXII gene that encode full-length protein were replaced by the exons 1~14 of human FXII gene in B-hFXII mice. 

Model validation


from clipboard
  • √: The experiment is planned.
  • NA: The experiment is not currently planned.
  • According to the characteristics and applications of the products, you can add experiments in the table by yourself.


mRNA expression analysis in humanized B-hFXII mice


from clipboard


Strain specific analysis of FXII mRNA expression in wild-type C57BL/6N mice and B-hFXII mice by RT-PCR. Liver RNA were isolated from wild-type C57BL/6N mice (+/+) and heterozygous B-hFXII mice (H/+), then cDNA libraries were synthesized by reverse transcription, followed by PCR with mouse or human FXII primers. Mouse FXII mRNA were detectable in wild-type C57BL/6N and heterozygous B-hFXII mice. Human FXII mRNA was only detectable in heterozygous B-hFXII mice. 


Protein expression analysis in humanized B-hFXII mice


from clipboard

Strain specific FXII expression analysis in homozygous B-hFXII mice by ELISA. Serum and plasma were collected from wild-type mice C57BL/6N mice (+/+) and homozygous B-hFXII mice (H/H) (n=3), and analyzed by ELISA with species-specific FXII ELISA kit. Mouse FXII was only detectable in wild-type mice (A). Human FXII was exclusively detectable in homozygous mice but not in wild-type mice (B). 

Summary

mRNA expression analysis:
Mouse FXII mRNA was detectable in liver of wild-type (+/+) and heterozygous B-hFXII mice (H/+) . Human FXII mRNA was detectable in heterozygous B-hFXII mice (H/+) mice but not in wild-type mice.
Protein expression analysis:
Human FXII was detectable in heterozygous B-hFXII mice (H/+) but not in wild-type mice (+/+).